What should be done about schizophrenia?
Schizophrenia remains one of the most intractable of all problems facing patients, their relatives and the health services. The neuroleptic drugs, starting with chlorpromazine and leading up to the present long-acting depot preparations, have had an enormous impact on the disease. Without them the policy of emptying the long-stay mental hospitals could not even have been contemplated. But anyone who is a member of or close to a family in which there is a neuroleptic-treated schizophrenic is fully aware that such drugs are far from providing a full answer. Complete normality is almost never obtained, and the side effects can 0141-0768/81/030180-03/$01.00/0 be distressing and severe. Rarely does one see a drug-treated schizophrenic fulfilling the potential apparent when he or she was, say, in the midteens. If employment is possible, the type of work is often menial, trivial and insecure. Particularly disturbing at present is the spectre of tardive dyskinesia, a side effect of treatment which is exceedingly distressing, which invariably initially worsens on drug withdrawal, and which in many may never be fully reversed. There is still much argument about how many drug-treated schizophrenics develop tardive dyskinesia, and how reversible it is, but there is little dispute that a serious crisis in psychiatric treatment is looming.
In the face of these problems, what is to be done? A complete solution would probablythough not necessarily require full understanding of the aetiology of the disease, a topic about which there is no agreement. Some believe that schizophrenia develops in the context of a particular type of family structure, some that it requires a particular type of social environment, some that it is caused by a biochemical defect, and some that is does not exist. Many find partial validity in most of the available hypotheses and recommend a mixed approach to treatment. The average well-adjusted British psychiatrist might therefore recommend judicious use of drugs coupled with an emphasis on social measures to regulate the patient's environment both in and out of the home. Unfortunately for the schizophrenic and his or her family, the outcome is too often thoroughly unsatisfactory. The improvement achieved by the drugs is limited, severe strains are placed on the family attempting to provide a suitable environment for a person whose susceptibility to stress may be utterly unreasonable, and the social and community services are inappropriate or do not exist.
In the mental health community the Schizophrenia Association of Great Britain (SAGO) strikes what to many seems a strident and discordant note. The SAGO is an organization of lay people, largely relatives and friends of schizophrenics and schizophrenics themselves. They have dared to challenge the well-balanced views of the mental health experts by coming out unequivocally in favour of the view that schizophrenia is a disease which has a biochemical cause, and which therefore will have a biochemical solution. They will have nothing to do with the family and social views of the causation of schizophrenia. They argue that by far the most urgent priority is to fund research to find the biochemical cause of the disease, since that will almost certainly lead to a genuine cure. They have little time for the multifactorial concepts of the establishment, except in the sense that schizophrenia may have a number of different (Q 1981 The Royal Society of Medicine primary' biochemical causes which lead to the same final common path. The main function of the SAGB is to stimulate biochemical research and to campaign for increased funding, while at the same time providing support and succour to those of their members who have been assaulted by psychiatrists and other mental health professionals putting much of the blame for the illness at the doors of the families.
Their argument is simple and to those who bother to listen it is not lacking in persuasiveness. The points they make are as follows:
(1) Only the biochemical hypothesis offers any real hope of doing something radical about schizophrenia.
Concepts which blame schizophrenia on the family or on the social environment are therapeutically hopeless, even if they should prove correct. To change families and the social environment in a way which would prevent schizophrenia is obviously an impossibility, yet an impossibility which provides a sink for unimaginable sums of money and the opportunity of well-paid careers for large numbers of professionals and semi-professionals.
(2) Schizophrenia is obviously multi-factorial in the sense that social and family pressures influence when it is expressed, the way in which it is expressed and perhaps even whether it is. expressed. But these other factors can operate only when a biochemical lesion is present, and are powerless to produce schizophrenia in the absence of such a lesion. The SAGB believes that the supposed multifactorial nature of schizophrenia will eventually prove similar to the multifactorial natures of tuberculosis or of polio. The principle of distinguishing between necessary and sufficient conditions can clearly be seen with these diseases. The necessary condition is the infectious agent: without that the disease cannot develop. But the infectious agent alone is not sufficient for the disease to develop. Other factors such as nutritional status and past medical history, which are heavily influenced by social and family factors, are required in addition. Manipulating these additional sufficient conditions will certainly influence the course of the disease. But such manipulation is likely to be inordinately expensive, as the example of the TB sanatoria shows. In contrast, eliminating the necessary condition may eliminate the disease relatively cheaply, even though all the other social and family factors remain unchanged. The SAGB believes that the necessary' condition in schizophrenia is a biochemical lesion. They fully recognize that many family and social influences will influence the expression of that lesion. But they argue that correction of these 'sufficient' conditions is a totally unrealistic aim, and one which puts impossible strains on relatives. What must be done is to find the lesion and so eliminate the necessary condition.
(3) There is already strong evidence that a biochemical lesion is likely to be present. The genetic studies,. the negative associations between schizophrenia and certain other diseases such as rheumatoid arthritis, and the partially favourable responses to drugs which go beyond mere sedation all make the idea of a biochemical lesion not unrealistic.
(4) Research is the only way in which the lesion will be found. The history of medicine suggests that the answer is perhaps more likely to be found among the unorthodox than among the orthodox -a statement which must not be misconstrued as meaning that anyone unorthodox approach is more likely to be right than anyone orthodox one. The SAGB is appalled at how little money is being spent on the search for a fundamental cause of schizophrenia, and at how relatively narrowly focused are the few projects which are being pursued. They would like to fund research themselves but in the absence of adequate resources they believe that the most useful approach is to organize conferences at which as many divergent views as possible of the biological basis of schizophrenia may be freely expressed. The idea is to force research workers to consider widely differing points of view and also to understand, by meeting the patients and families who are at the conferences, just what the real problems of the disease are.
The SAGB held its 1980 conference on 24 and 25 September at Bedford College, London. These conferences are like no others I have ever attended in the medical field, and they are outstandingly successful. Patients, relatives, laboratory researchers, clinical phychiatrists, the narrowly orthodox and the fringe are forced together in an atmosphere which, possibly because of the presence of lay people, is remarkably friendly. No one whose mind is not already completely closed on the subject could fail to learn some things which are novel and possibly important.
As far as research is concerned, the tide seems to be flowing the SAGB's way. Several years ago the SAGB began to champion the then fringe idea that certain proteins, such as alpha-casein and gluten, could cause dramatic mental disturbances in susceptible people. Over the last two years that view has become respectable with the findings of Zioudrou and her colleagues (1979) at the National Institutes of Health in Washington, that digestion of these proteins leads to the production in the gut of opioid peptides which may be absorbed into the blood. The SAGB has also supported the concept that there may be immunological problems in schizophrenia, and again the evidence is now becoming convincing.
The 1980 conference, like previous ones, showed that the SAGB can attract outstanding researchers, such as Professor L Wetterberg Head of Psychiatry at the Karolinska Institute, Stockholm; Dr L Terenius from Uppsala; Dr T Crow, Head of the MRC Unit at Northwick Park; and Dr J Rotrosen and Dr A Mathe from leading psychiatric research groups in the USA. The roles of genetics, of opioids, of dopamine, of steroids, of prostaglandins, of nutritional factors and of immunology were all discussed and argued about in considerable detail. Wetterberg's genetic studies in a geographically isolated population in the far north of Sweden must convince all but the most wilfully ignorant of the strong genetic component in the disease. Terenius of Uppsala and Edminson of Oslo presented results showing that the evidence of abnormal opioid production in schizophrenics is now more convincing. Rotrosen and Mathe from New York demonstrated clearcut abnormalities of prostaglandin synthesis and action in schizophrenics which could not be attributed to drug treatment. Since opioids can modulate prostaglandin production it seems possible that the abnormalities described by Terenius and Edminson may be the causes of those described by Rotrosen and Mathe. Vaddadi from Leeds presented clinical studies indicating that therapies aimed at modifying prostaglandin synthesis can have substantial effects, so opening up radically new possibilities of therapy. Abdullah from Guy's Hospital, London, described a new form of C-reactive protein which may prove specific to schizophrenics. These were but a few of the many papers presented.
The SAGB may be wrong. The growing feeling that something substantial is happening in schizophrenia research may be an expression of false hope. It may be impossible to find and correct a biochemical lesion. On the other hand, the findings presented at the Bedford College meeting may indicate that before long radically new types of schizophrenia therapy will be introduced. If this does occur the SAGB will deserve much of the credit for banging the heads of the researchers together and encouraging them to think along new and productive lines. It is to be hoped that the authorities responsible for research funding in Britain take note of what is happening and provide the money to enable these developments to push ahead as rapidly as possible.
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